Effect of high-dose Statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure - Randomized, controlled, open-label, prospective pilot study

Jaewon Oh, Seok Min Kang, Namki Hong, Jong Chan Youn, Sungha Park, Sang Hak Lee, Donghoon Choi

Research output: Contribution to journalArticle

Abstract

Background: High-dose statin loading is known to reduce periprocedural myocardial infarction and contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. However, the clinical role of high-dose statin loading in patients with acute heart failure (AHF) remains unknown.

Methods and Results: In a prospective, single-center, randomized, controlled, open-label pilot study, patients hospitalized with AHF were randomly assigned to receive oral high-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge) or no statin therapy, on top of optimal HF treatment. The primary outcome measures were changes to the level of biomarkers related to inflammation and renal injury from admission to hospital day 4. No significant changes in the levels of NT-proBNP (-2,627±4,956 vs. -2,981±6,951 pg/ml, P=0.845), hsCRP (-6.1±16.4 vs. -2.1±16.2 mg/L, P=0.105), cystatin C (0.002±0.185 vs. 0.009±0.216 mg/L, P=0.904), ACR (-886.3±1,984.9 vs. -165.6±825.2 mg/day, P=0.124) were observed in either group. In-hospital mortality (4.3% vs. 3.8%, P>0.999) and all-cause mortality at 90 days (4.3% vs. 3.8%, P>0.999) were not significantly different between groups.

Conclusions: This pilot study showed that oral high-dose atorvastatin loading may be used safely in patients with AHF, but is not effective in reducing the levels of circulating biomarkers related to inflammation and renal injury during hospitalization.

Original languageEnglish
Pages (from-to)2447-2454
Number of pages8
JournalCirculation Journal
Volume78
Issue number10
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Heart Failure
Biomarkers
Prospective Studies
Inflammation
Kidney
Wounds and Injuries
Cystatin C
Percutaneous Coronary Intervention
Hospital Mortality
Acute Kidney Injury
Hospitalization
Myocardial Infarction
Outcome Assessment (Health Care)
Mortality
Therapeutics
Atorvastatin Calcium

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{95732d07f1a846bc94c07cd16999da34,
title = "Effect of high-dose Statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure - Randomized, controlled, open-label, prospective pilot study",
abstract = "Background: High-dose statin loading is known to reduce periprocedural myocardial infarction and contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. However, the clinical role of high-dose statin loading in patients with acute heart failure (AHF) remains unknown.Methods and Results: In a prospective, single-center, randomized, controlled, open-label pilot study, patients hospitalized with AHF were randomly assigned to receive oral high-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge) or no statin therapy, on top of optimal HF treatment. The primary outcome measures were changes to the level of biomarkers related to inflammation and renal injury from admission to hospital day 4. No significant changes in the levels of NT-proBNP (-2,627±4,956 vs. -2,981±6,951 pg/ml, P=0.845), hsCRP (-6.1±16.4 vs. -2.1±16.2 mg/L, P=0.105), cystatin C (0.002±0.185 vs. 0.009±0.216 mg/L, P=0.904), ACR (-886.3±1,984.9 vs. -165.6±825.2 mg/day, P=0.124) were observed in either group. In-hospital mortality (4.3{\%} vs. 3.8{\%}, P>0.999) and all-cause mortality at 90 days (4.3{\%} vs. 3.8{\%}, P>0.999) were not significantly different between groups.Conclusions: This pilot study showed that oral high-dose atorvastatin loading may be used safely in patients with AHF, but is not effective in reducing the levels of circulating biomarkers related to inflammation and renal injury during hospitalization.",
author = "Jaewon Oh and Kang, {Seok Min} and Namki Hong and Youn, {Jong Chan} and Sungha Park and Lee, {Sang Hak} and Donghoon Choi",
year = "2014",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-14-0670",
language = "English",
volume = "78",
pages = "2447--2454",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",

}

TY - JOUR

T1 - Effect of high-dose Statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure - Randomized, controlled, open-label, prospective pilot study

AU - Oh, Jaewon

AU - Kang, Seok Min

AU - Hong, Namki

AU - Youn, Jong Chan

AU - Park, Sungha

AU - Lee, Sang Hak

AU - Choi, Donghoon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: High-dose statin loading is known to reduce periprocedural myocardial infarction and contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. However, the clinical role of high-dose statin loading in patients with acute heart failure (AHF) remains unknown.Methods and Results: In a prospective, single-center, randomized, controlled, open-label pilot study, patients hospitalized with AHF were randomly assigned to receive oral high-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge) or no statin therapy, on top of optimal HF treatment. The primary outcome measures were changes to the level of biomarkers related to inflammation and renal injury from admission to hospital day 4. No significant changes in the levels of NT-proBNP (-2,627±4,956 vs. -2,981±6,951 pg/ml, P=0.845), hsCRP (-6.1±16.4 vs. -2.1±16.2 mg/L, P=0.105), cystatin C (0.002±0.185 vs. 0.009±0.216 mg/L, P=0.904), ACR (-886.3±1,984.9 vs. -165.6±825.2 mg/day, P=0.124) were observed in either group. In-hospital mortality (4.3% vs. 3.8%, P>0.999) and all-cause mortality at 90 days (4.3% vs. 3.8%, P>0.999) were not significantly different between groups.Conclusions: This pilot study showed that oral high-dose atorvastatin loading may be used safely in patients with AHF, but is not effective in reducing the levels of circulating biomarkers related to inflammation and renal injury during hospitalization.

AB - Background: High-dose statin loading is known to reduce periprocedural myocardial infarction and contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. However, the clinical role of high-dose statin loading in patients with acute heart failure (AHF) remains unknown.Methods and Results: In a prospective, single-center, randomized, controlled, open-label pilot study, patients hospitalized with AHF were randomly assigned to receive oral high-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge) or no statin therapy, on top of optimal HF treatment. The primary outcome measures were changes to the level of biomarkers related to inflammation and renal injury from admission to hospital day 4. No significant changes in the levels of NT-proBNP (-2,627±4,956 vs. -2,981±6,951 pg/ml, P=0.845), hsCRP (-6.1±16.4 vs. -2.1±16.2 mg/L, P=0.105), cystatin C (0.002±0.185 vs. 0.009±0.216 mg/L, P=0.904), ACR (-886.3±1,984.9 vs. -165.6±825.2 mg/day, P=0.124) were observed in either group. In-hospital mortality (4.3% vs. 3.8%, P>0.999) and all-cause mortality at 90 days (4.3% vs. 3.8%, P>0.999) were not significantly different between groups.Conclusions: This pilot study showed that oral high-dose atorvastatin loading may be used safely in patients with AHF, but is not effective in reducing the levels of circulating biomarkers related to inflammation and renal injury during hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=84908242091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908242091&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-14-0670

DO - 10.1253/circj.CJ-14-0670

M3 - Article

C2 - 25168278

VL - 78

SP - 2447

EP - 2454

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -